Compare Nvidia Corp (NVDA) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nvidia Corp vs ResMed Inc. — how do they compare? Nvidia Corp trades at $235.02 (market cap $5.57T), while ResMed Inc. trades at $225.92 (market cap $31.89B). The key difference: Nvidia Corp is far larger — about 174.7× ResMed Inc.'s market cap, and ResMed Inc. pays the higher dividend (1.16%). Which is the better fit depends on your goals — on Pluang, investors hold Nvidia Corp for 115 Days and ResMed Inc. for 51 Days on average.
| NVDA | RMD | |
|---|---|---|
Market Cap | $5.57T | $31.89B |
Volume | 117,720,595 | 618,314 |
Sector | Technology | Health |
52-Week High | $239.27 | $277.88 |
52-Week Low | $165.17 | $182.82 |
Typical Hold Time | 115 Days | 51 Days |
Enterprise Value | $5.54T | $31.24B |
Dividend Yield | 0.43% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVIDIA (NVDA) trades at $237.36, down 0.8% on the day, amid strong fundamental performance with revenue surging to $130.5 billion in 2025 and net income reaching $72.88 billion. The stock maintains a bullish technical outlook with moving averages signaling strength, though RSI levels suggest potential overbought conditions. Recent earnings beats and a 75.95% analyst buy rating support positive sentiment, while the company's dominant position in AI chips drives continued growth expectations.
Outlook remains positive with a consensus price target of $339.17 representing significant upside potential. Key opportunities include sustained AI demand and expanding market leadership, while risks involve increased competition, peak AI spending concerns, and valuation metrics above industry averages. The stock's current valuation reflects high growth expectations that must be met to justify further appreciation.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical signal and strong fundamentals. Revenue grew to $5.15B in 2025, with net income at $1.40B and a 26.94% net margin. Recent earnings beats and a 12-14% EPS growth outlook support momentum. The stock is near its pivot point of $227, with support at $225 and resistance at $228.
Outlook is positive with analyst consensus at Buy and a $242.70 price target. Risks include competitive pressures and ongoing legal investigations. Institutional buying and solid cash flow growth underpin the bullish case, though macroeconomic and regulatory factors warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
